• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by BriaCell Therapeutics Corp. (Amendment)

    9/20/21 5:25:21 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    SC 13D/A 1 p92212sc13da1.htm AMENDMENT NO. 1

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 1)1

     

    BriaCell Therapeutics Corp.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    10778Y302

    (CUSIP Number)

     

    Milton C. Ault, III

    AULT GLOBAL Holdings, Inc.

    11411 Southern Highlands Parkway, Suite 240

    Las Vegas, NV 89141

    (949) 444-5464

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    September 16, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

                                  

    1       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      
     

     

    CUSIP No. 10778Y302

     

     

    1

    NAME OF REPORTING PERSONS

     

    Ault Global Holdings, Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) o

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    715,000 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    715,000 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    715,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.67%

    14

    TYPE OF REPORTING PERSON

     

    CO

     

    (1) Represents (i) 675,000 Common Shares held by Digital Power Lending, LLC and (ii) 40,000 Common Shares underlying current exercisable warrants held by Digital Power Lending, LLC.

     

     - 2 - 
     

     

    CUSIP No. 10778Y302

     

     

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”) on August 9, 2021 (the “Schedule 13D”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. Except as otherwise specified in this Amendment No. 1, all items in the Schedule 13D are unchanged. All capitalized terms used in this Amendment No. 1 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    The Shares and warrants purchased by AGH as reported on the Schedule 13D were purchased with working capital in open market purchases. AGH expended an aggregate of $4,465,260.32 for the purchase of the Shares and warrants.

     

    The Shares and warrants traded by AGH subsequent to the Schedule 13D reduced AGH’s aggregate expenditures by $1,239,592.45. Consequently, as of the date of this Amendment No. 1, AGH expended an aggregate amount of $3,225,667.87 for the purchase of the Shares and warrants.

     

    Item 5.Interest in Securities of the Issuer.

     

    The aggregate percentage of Shares reported owned by the Reporting Person herein is based upon 15,269,583 Shares outstanding, which is the total number of Shares outstanding as of September 8, 2021, as reported in a press release from the Issuer, attached as an exhibit to the Report of Foreign Private Issuer on Form 6-K, filed with the Securities and Exchange Commission on September 9, 2021.

     

    AGH

     

    (a) As of the close of business on September 17, 2021, AGH beneficially owned 715,000 Shares, consisting of (i) 675,000 Common Shares held by Digital Power Lending, LLC and (ii) 40,000 Common Shares underlying current exercisable warrants held by Digital Power Lending, LLC.

     

    Percentage: Approximately 4.67%

     

    (b) 1. Sole power to vote or direct vote: 715,000
    2. Shared power to vote or direct vote: None
    3. Sole power to dispose or direct the disposition: 715,000
    4. Shared power to dispose or direct the disposition: None

     

    (c)AGH has not entered into any transactions in the Shares during the past sixty days except for the open market transactions conducted by its wholly-owned subsidiary Digital Power Lending, LLC set forth below.

     

    Digital Power Lending, LLC

     

    Digital Power Lending, a wholly-owned subsidiary of AGH, engaged in the following transactions in the Shares since August 16, 2021:

     

    Date Transaction Quantity Weighted Average Price
    8-16-21 Purchase 3,000 $5.58
    8-18-21 Sale (1,000) $5.73
    8-26-21 Sale (5,000) $6.19
    8-26-21 Purchase 6,000 $6.09
    8-27-21 Sale (5,000) $6.44
    8-30-21 Sale (4,000) $6.81
    8-31-21 Sale (2,000) $6.95
    9-8-21 Sale (12,000) $7.22
    9-9-21 Sale (40,000) $8.05
    9-10-21 Sale (10,000) $7.94
    9-13-21 Sale (10,000) $7.70
    9-16-21 Sale (40,352) $7.54
    9-17-21 Sale (34,648) $7.71

     

     - 3 - 
     

     

    CUSIP No. 10778Y302

     

     

    Digital Power Lending, a wholly-owned subsidiary of AGH, engaged in the following transactions in Warrants since September 8, 2021:

     

    Nature of the
    Transaction
    Number of
    Shares
    Underlying
    Warrant
    Warrant Sale
    Price per Warrant
    Share ($)

     

     

    Expiration
    Date

     

     

    Exercise
    Price ($)

    Date of
    Purchase/Sale
    Sale of Common
    Stock Warrant
    (5,000) 2.99

     

     

    February 26, 2026

     

     

     

    5.3125

    09/08/2021
    Sale of Common
    Stock Warrant
    (2,500) 3.25

     

     

    February 26, 2026

     

     

     

    5.3125

    09/09/2021
    Sale of Common
    Stock Warrant
    (2,500) 3.12

     

     

    February 26, 2026

     

     

     

    5.3125

    09/10/2021
    Sale of Common
    Stock Warrant
    (1,000) 3.09

     

     

    February 26, 2026

     

     

     

    5.3125

    09/13/2021
    Sale of Common
    Stock Warrant
    (1,500) 2.90

     

     

    February 26, 2026

     

     

     

    5.3125

    09/16/2021
    Sale of Common
    Stock Warrant
    (2,500) 3.07

     

     

    February 26, 2026

     

     

     

    5.3125

    09/17/2021

     

    (d)No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    (e) Effective as of the close of business on September 16, 2021, the Reporting Person ceased to be the beneficial owner of more than five percent of the class of securities.

     

     - 4 - 
     

     

    CUSIP No. 10778Y302

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. 

     

    Dated:      September 20, 2021

     

      AULT GLOBAL HOLDINGS, INC.
         
      By:  /s/ Milton C. Ault, III
       

    Milton C. Ault, III

    Executive Chairman

     

     

     

     

      DIGITAL POWER LENDING, LLC
         
      By:  /s/ David J. Katzoff
       

    David J. Katzoff

    Manager

     

     

    - 5 -

     

     

    Get the next $BCTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

    2/14/22 6:04:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

    Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvem

    1/28/26 7:30:00 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

    9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchma

    1/27/26 7:30:00 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Therapeutics Announces Closing of US$30 million Public Offering

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit was sold to the public at a price of US$5.59 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately US$30 million, before deduct

    1/15/26 4:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

    SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)

    1/23/26 6:59:18 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

    1/15/26 4:15:57 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by BriaCell Therapeutics Corp.

    424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)

    1/14/26 4:15:34 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 4:38:08 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Williams William V.

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 3:22:52 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/12/24 6:06:07 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/10/24 6:06:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/5/24 7:45:06 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

    PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

    2/5/25 6:15:47 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

    1/3/25 5:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

    PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

    12/17/24 4:05:59 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

    The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

    7/7/23 8:10:00 AM ET
    $BCTX
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care